The research team, led by investigators at Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School, took an unusually comprehensive approach, weaving together human proteomics, a prospective surgical cohort, and mechanistic experiments in mice and cultured neurons. Their starting point was the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large longitudinal study in which cerebrospinal fluid from thousands of participants has been profiled using the SomaScan 7K platform, an aptamer-based technology capable of measuring more than 7,000 molecular analytes simultaneously. From this resource, the researchers defined an exploratory phenotype they call neurodegeneration-enriched cognitive vulnerability, or NECV: individuals with mild cognitive impairment who also had a documented history of surgery. By comparing the proteomic fingerprints of 152 NECV participants against 85 cognitively normal controls, and applying stringent Bonferroni correction across more than 6,000 unique proteins, they found that 14-3-3γ ranked among the top candidates, occupying a central position in the co-expression network of disease-relevant proteins.

The signal held up under scrutiny. Cerebrospinal fluid levels of 14-3-3γ were dramatically elevated in the NECV group compared with controls, a difference that reached an extraordinary statistical significance of p = 7.8 × 10⁻³². The finding replicated independently in the Parkinson’s Progression Markers Initiative (PPMI) cohort and was further confirmed in autopsy-verified Alzheimer’s disease samples. Crucially, the protein was not merely a static marker. In longitudinal survival analyses, participants with higher baseline CSF 14-3-3γ faced an increased hazard of progressing from normal cognition to prodromal Alzheimer’s disease, and those already in the vulnerable group progressed more rapidly to frank dementia. Elevated 14-3-3γ also tracked with the classic molecular hallmarks of neurodegeneration: lower CSF amyloid-beta 42, higher phosphorylated and total tau, greater cortical amyloid burden on PET imaging, smaller hippocampal volumes, reduced cerebral glucose metabolism, and steeper declines in memory, executive function, and global cognition over time.

What elevates this work beyond biomarker correlation is its translation into the surgical setting. The team prospectively enrolled 213 patients aged 65 and older undergoing major elective cardiac, orthopedic, or aortic surgery at their tertiary center, a study registered with the Chinese Clinical Trial Registry. Blood drawn on the first postoperative day, before any delirium had been documented, revealed that patients who subsequently developed postoperative delirium or POCD had significantly higher circulating 14-3-3γ levels than those who recovered uneventfully. In this cohort, 22 patients (10.3 percent) developed delirium within the first week, while 11 (5.2 percent) met criteria for POCD at day seven, all consistent with delayed neurocognitive recovery under the 2018 nomenclature consensus. When plasma 14-3-3γ was added to models built from routine clinical variables, predictive performance improved substantially: the area under the receiver operating characteristic curve for delirium rose from 0.819 to 0.921, and for POCD from 0.705 to 0.864, with statistically significant gains confirmed by DeLong tests. Decision curve and precision-recall analyses suggested the combined models offered genuine net clinical benefit, though the authors are careful to frame these findings as exploratory given the modest number of outcome events.

One of the most intriguing puzzles the study surfaces is a striking compartmental divergence. After surgery, 14-3-3γ levels fell markedly inside hippocampal neurons in mice, yet rose in the blood and cerebrospinal fluid of both mice and humans. The researchers propose that the extracellular elevation reflects a spillover phenomenon, a leakage of intracellular proteins from injured neurons, a pattern long recognized in conditions such as Creutzfeldt-Jakob disease, stroke, and traumatic brain injury, where CSF 14-3-3 proteins serve as markers of neuronal damage. The intracellular depletion, by contrast, may be the pathologically decisive event. The 14-3-3 family constitutes roughly one percent of total soluble brain protein, and its loss would destabilize a web of protein-protein interactions governing tau phosphorylation, mitochondrial function, and synaptic maintenance. In other words, the protein leaking into the bloodstream may be a useful warning signal, but the deficit left behind inside vulnerable neurons is what drives the damage.

To establish causality, the team turned to a murine model of perioperative brain injury in which mice undergo tibial fracture with intramedullary fixation under isoflurane anesthesia, a procedure that recapitulates key clinical features of major orthopedic surgery, including tissue trauma, inflammation, and postoperative pain. Within days, surgically treated mice showed impaired performance in the Y-maze spontaneous alternation test and contextual fear conditioning, both hippocampus-dependent tasks, while locomotor activity and cued memory remained intact, pointing to a specific rather than global deficit. Electron microscopy revealed fragmented microtubules, the intracellular highways that tau normally stabilizes. Golgi staining showed a loss of mature dendritic spines, the tiny protrusions where synapses form. Levels of the synaptic proteins PSD95 and synaptophysin dropped, synaptic clefts widened, and postsynaptic densities thinned. Biochemically, the surgery produced a selective and sustained hyperphosphorylation of tau at the threonine 205 residue, detectable and pronounced at postoperative day seven, while other phosphorylation sites examined, including Thr231, Ser396, and Ser262, remained unchanged at that timepoint.

The mechanistic thread connecting 14-3-3γ loss to tau damage runs through the enzymes that control tau’s phosphorylation state. When the researchers silenced 14-3-3γ in HT22 hippocampal cells, they observed activation of CDK5, reflected in an increased p25-to-p35 ratio; activation of GSK3β, seen as reduced inhibitory phosphorylation at Ser9; and inhibition of the phosphatase PP2A, marked by increased phosphorylation at Tyr307. The net effect was a shift toward kinase-dominated regulation of tau, and tau Thr205 phosphorylation climbed accordingly. Pharmacologically damping CDK5 with roscovitine, blocking GSK3β with lithium chloride, or activating PP2A with DT061 each reversed the hyperphosphorylation. Co-immunoprecipitation experiments added a structural dimension: loss of 14-3-3γ reduced the association of phosphorylated tau with the protective phosphatase PP2A while increasing its association with the kinases CDK5 and GSK3β. Immunoprecipitation followed by mass spectrometry independently identified tau as a binding partner of 14-3-3γ, and the interaction proved sensitive to the Thr205 phosphorylation state, with a phospho-mimetic T205E tau mutant binding more strongly and a phospho-deficient T205A mutant binding more weakly.

The therapeutic implications emerged from two elegant intervention experiments. First, when the researchers delivered a gene therapy vector carrying 14-3-3γ directly into the hippocampal CA1 region and dentate gyrus of mice via adeno-associated virus, the overexpression suppressed surgery-induced tau Thr205 hyperphosphorylation, restored microtubule integrity and synaptic architecture, recovered dendritic spine density, and rescued working memory and contextual fear memory. Second, and perhaps most provocatively, the team tested fusicoccin-A, a small molecule known to stabilize 14-3-3 protein-protein interactions. Administered intraperitoneally before surgery, fusicoccin-A enhanced the binding between 14-3-3γ and phosphorylated tau, restored their colocalization in hippocampal neurons, rescued synaptic protein levels, reduced tau Thr205 phosphorylation without altering total tau, and improved cognitive performance in the Y-maze and fear conditioning tests. Molecular dynamics simulations running 500 nanoseconds per system showed that fusicoccin-A binding shortened the center-of-mass distance between the two proteins, reduced structural fluctuation, and rendered the binding free energy more favorable, providing a physical basis for the stabilization. Critically, when the researchers expressed a phosphomimetic TauT205E mutant in the hippocampus, the mutant alone was sufficient to impair cognition, and it abolished the protective effect of fusicoccin-A, demonstrating that tau Thr205 phosphorylation sits downstream in the protective pathway.

The authors are candid about the limitations that temper these exciting results. The ADNI-based discovery analysis is hypothesis-generating rather than direct evidence about POCD, since that cohort lacks detailed perioperative data. The prospective surgical cohort, though consecutively enrolled, produced few outcome events, limiting the robustness of the prediction models. The mouse experiments used young adult male animals rather than the aged populations most at risk clinically, and only a single small-molecule modulator was tested, leaving dose-response relationships, chronic effects, and safety profiles unexplored. Species differences in 14-3-3 regulation and tau dynamics may also affect translational relevance. Nevertheless, the study represents a genuine conceptual advance: it elevates 14-3-3γ from a passive correlate of neurodegeneration to an active, druggable regulator of acute cognitive vulnerability, and it points toward a strategy for protecting the surgical brain that is fundamentally different from conventional anti-amyloid or anti-tau therapies. If larger, multicenter trials confirm that a simple postoperative blood test for 14-3-3γ can flag patients at risk, and if stabilizers of the 14-3-3γ-tau interaction can be developed into safe drugs, the era of passively watching surgical patients lose their cognitive edge may finally give way to one of prediction and prevention.

Subject of Research: The role of 14-3-3γ in regulating tau Thr205 phosphorylation and synaptic integrity in postoperative cognitive dysfunction

Article Title: 14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

Article References: Zhu, S., Han, X., Zhang, H., Ye, C., Xia, T., & Gu, X. (2026). 14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity. Advanced Science, Article e77480. https://doi.org/10.1002/advs.77480

Image Credits: AI Generated

DOI: 10.1002/advs.77480

Keywords: postoperative cognitive dysfunction, 14-3-3γ, YWHAG, tau phosphorylation, Thr205, synaptic integrity, biomarker, postoperative delirium, fusicoccin-A, CSF proteomics, hippocampus, neurodegeneration

A new study published in the Journal of Advanced Research offers a strikingly different approach to attacking tau at its upstream source. Rather than blocking the activity of one of tau’s key dysregulating kinases, the research team designed a small molecule that eliminates the kinase protein itself. The target is death-associated protein kinase 1, or DAPK1, an enzyme that has accumulated an impressive pathogenic dossier in Alzheimer’s research. DAPK1 activates MARK1/2 to trigger abnormal tau phosphorylation, directly phosphorylates tau at disease-relevant residues, and through phosphorylation of SENP1 promotes tau SUMOylation, exacerbating tau pathology and cognitive dysfunction. Genetic knockdown and pharmacological inhibition of DAPK1 have both been shown to reduce tau phosphorylation and mitigate neurodegeneration in cell and animal models. Yet traditional small-molecule kinase inhibitors suffer from well-known drawbacks: short-lived efficacy, compensatory signaling from parallel pathways, and substantial off-target liability.

To overcome these limitations, the team turned to targeted protein degradation, a next-generation pharmacological strategy that hijacks the cell’s own proteostasis machinery. Their specific platform is hydrophobic tagging, or HyT, in which a bifunctional molecule couples a ligand that binds the protein of interest to a bulky hydrophobic moiety, typically adamantane, that mimics the exposed greasy surfaces of misfolded proteins. The cell’s quality-control machinery is fooled into ubiquitinating the tagged protein and destroying it via the ubiquitin-proteasome system. Adamantane-based hydrophobic tags carry distinct advantages over the better-known PROTAC degraders: simpler molecular design, lower molecular weight, favorable ADME characteristics, and high degradation efficiency. The approach has already been used to degrade tau, TDP-43, and mutant huntingtin, but it had never been applied to DAPK1.

From a library of candidate degraders built by conjugating a previously characterized DAPK1-binding ligand to adamantane- or fluorene-based hydrophobic tags through alkylamine linkers of varying length, one compound emerged as the clear leader. Named CJ1, the molecule reduced DAPK1 protein levels in mouse primary cortical neurons to roughly half of control levels at a screening concentration of 1 micromolar, outperforming all other compounds in the series. Molecular docking suggested that CJ1’s DAPK1-binding moiety occupies a distinct hydrophobic pocket on the kinase surface, with favorable electrostatic complementarity at the binding interface. Critically, cytotoxicity testing showed that CJ1 did not compromise the viability of primary neurons even at concentrations up to 20 micromolar, providing a wide margin between functional activity and cellular harm.

The mechanistic characterization of CJ1 was rigorous. In primary cortical neurons, the compound degraded DAPK1 in a dose-dependent fashion, with a half-maximal degradation concentration of approximately 0.18 micromolar, and a time course showing detectable degradation beginning four hours after treatment and sustained suppression lasting up to 48 hours. Quantitative PCR confirmed that DAPK1 mRNA levels were unchanged, indicating a posttranslational mechanism. When cells were pretreated with the proteasome inhibitor MG-132, CJ1-induced degradation was abolished, and ubiquitination assays demonstrated markedly increased polyubiquitinated DAPK1 in the presence of the compound. Together, these experiments established that CJ1 marks DAPK1 for ubiquitin-dependent proteasomal destruction, precisely the event-driven behavior expected of a hydrophobic tagging degrader.

With the mechanism confirmed, the investigators asked whether eliminating DAPK1 would tame tau. In primary cortical neurons, SH-SY5Y neuroblastoma cells, and SH-SY5Y cells expressing the P301L mutant human tau, CJ1 treatment reduced levels of tau phosphorylated at threonine 231, serine 262, and serine 396, along with total tau. These phosphorylation sites are deeply meaningful in Alzheimer’s biology: phosphorylation at Ser262 within the microtubule-binding repeat domain critically weakens tau’s grip on microtubules, Thr231 primes tau for further phosphorylation by GSK3beta and contributes to microtubule destabilization, and the Ser396/404 epitope marks advanced pathological tau. Several control experiments reinforced the specificity of the effect. CJ1 did not alter the levels of the major tau kinases GSK3beta and CDK5, the phosphatase PP2A, or the related kinase DAPK3. In DAPK1 knockout neurons, CJ1 lost its ability to reduce tau or phospho-tau, and a control compound lacking the DAPK1-binding moiety was inert. Overexpressing DAPK1 in cells also rescued the phenotype, strongly arguing that CJ1 acts specifically through DAPK1 degradation rather than through incidental off-target effects.

The in vivo results were the most consequential. A central hurdle for any Alzheimer’s therapeutic is crossing the blood-brain barrier, and liquid chromatography-mass spectrometry confirmed that intact CJ1 was detectable in mouse brain after systemic administration. In a tauopathy model created by injecting an adeno-associated virus carrying human P301L tau into the hippocampal CA3 region, DAPK1 was upregulated and CJ1 treatment lowered it in a dose-dependent manner, with 10 milligrams per kilogram nearly restoring baseline levels. CJ1 reduced human tau accumulation and phosphorylation at Thr231 and the AT8 epitope in the hippocampus. In aged hTau transgenic mice, which express all six human tau isoforms and develop genuine neurofibrillary tangles, five weeks of CJ1 treatment significantly reduced tangle burden in the cortex and lowered total tau and phospho-tau at multiple AD-relevant sites in both sarkosyl-soluble and, importantly, sarkosyl-insoluble fractions, the biochemical signature of aggregated, pathological tau.

Pathology translated into preserved brain structure and function. CJ1-treated tauopathy mice retained more NeuN-positive neurons, showed restored MAP2 immunoreactivity indicating healthier dendrites, and displayed dose-dependent recovery of dendritic spine density on Golgi-Cox staining. Neuroinflammation also receded: astrocytic activation marked by GFAP and microglial activation marked by Iba1 were both suppressed, pro-inflammatory iNOS decreased, and anti-inflammatory Arg-1 increased. Functionally, in the Morris water maze, CJ1-treated mice learned the platform location faster, spent more time in the target quadrant during the probe trial, and crossed the former platform location more often, with all groups swimming at comparable speeds, ruling out motor confounds. Notably, only the higher dose produced cognitive improvement, suggesting that partial biochemical correction of tau pathology is insufficient and that robust suppression is required for behavioral benefit.

Safety data were encouraging. CJ1 showed negligible hemolysis at concentrations up to 800 micrograms per milliliter, serum creatinine, ALT, and AST remained within normal ranges, and histological examination of the heart, liver, lung, and kidney revealed no treatment-related abnormalities. The authors are candid about limitations: the behavioral findings derive from an acute, region-specific model; the selectivity screen covered only a small panel of proteins; and the detailed brain distribution of CJ1 remains unmapped, as do potential differential effects on 3R versus 4R tau isoforms. Nonetheless, the study establishes CJ1 as a first-in-class DAPK1 degrader and provides a compelling proof of concept that hydrophobic tagging can eliminate an upstream driver of tau pathology inside cells, something neither conventional kinase inhibitors, which transiently block catalytic activity, nor tau immunotherapies, which target extracellular aggregates, can accomplish. By abolishing all of DAPK1’s functional domains and scaffolding roles in a catalytic, substoichiometric manner, this degrader strategy offers a mechanistically distinct and potentially more durable route to slowing the neurodegeneration that lies at the heart of Alzheimer’s disease.

Subject of Research: A hydrophobic tagging degrader that selectively eliminates DAPK1 to attenuate tau pathology in Alzheimer's disease

Article Title: Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer’s disease

Article References: Li, R., Wu, X., Yao, J., Chen, J., Shui, X., Zheng, X., Tian, W., Wang, L., Zhou, Y., Zhang, T., Chen, D., Liu, Y., & Lee, T. H. (2026). Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer’s disease. Journal of Advanced Research, 87, 1027-1043. https://doi.org/10.1016/j.jare.2025.12.037

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.037

Keywords: Alzheimer's disease, DAPK1, tau pathology, hydrophobic tagging, targeted protein degradation, neurofibrillary tangles, proteasome, tau phosphorylation, blood-brain barrier, neurodegeneration, drug discovery, tauopathy